"TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir (TMC114/r) in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications."

PHASE3CompletedINTERVENTIONAL
Enrollment

692

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

May 31, 2012

Conditions
HIV
Interventions
DRUG

LPV/RTV

400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks

DRUG

TMC-114/RTV

two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks

Trial Locations (89)

Unknown

Phoenix

Beverly Hills

Long Beach

Los Angeles

Sacramento

San Francisco

Washington D.C.

Fort Lauderdale

Jacksonville

Miami

Miami Beach

Orlando

Safety Harbor

Tampa

Vero Beach

Baltimore

Boston

Las Vegas

Brooklyn

Chapel Hill

Winston-Salem

Philadelphia

Columbia

Houston

Buenos Aires

Mar del Plata

Neuquén

Brisbane

Darlinghurst

Surry Hills

Westmead

Vienna

Brussels

Ghent

Leuven

Vancouver

Ottawa

Toronto

Montreal

Providencia

Santiago

Costa Rica

San José

Aalborg

Copenhagen Ø

Hvidovre

Bobigny

Lyon

Nice

Orléans

Paris

Berlin

Cologne

Erlangen

Freiburg im Breisgau

Hamburg

Mannheim

Munich

München

Athens

Guatemala City

Sungai Buloh

Del Tlalpan

Guadalajara

Mex Ctity

Mexico City

Panama City

San Juan

Kazan'

Krasnodar

Moscow

Saint Petersburg

Smolensk

Volgograd

Voronezh

Singapore

Cape Town

Dundee

Johannesburg

Pretoria

Barcelona

Zurich

Taipei

Tiachung

Bangkok

Chiang Mai

Khon Kaen

Brighton

London

All Listed Sponsors
lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00258557 - "TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir (TMC114/r) in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications." | Biotech Hunter | Biotech Hunter